Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome
Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome
Recruiting · NCT07135050 · Registry updated 2026-07-31Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome | Pitt-Hopkins syndrome | Recruiting | Phase 1 / Phase 2 | 2026-07-31 | NCT07135050 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| California Institute for Regenerative Medicine (CIRM) | 36 |
| Mahzi Therapeutics | 1 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Children's Hospital Colorado | Aurora | United States | 312 |
| Rush University Medical Center | Chicago | United States | 283 |
| Sheba Medical Center | Tel Litwinsky | Israel | 14 |
| UCSF Benioff Children's Hospital Oakland | Oakland | United States | 85 |